MedTrace Logo

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

NCT01717170 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-04-28

No results posted yet for this study

Summary

In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

Conditions

  • Intermediate Uveitis
  • Posterior Uveitis
  • Pan-uveitis

Interventions

DRUG

Tocilizumab

Tocilizumab (4 mg/kg or 8 mg/kg)

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Quan D Nguyen, MD, MSc · Truhlsen Eye Institute, University of Nebraska Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717170 on ClinicalTrials.gov